{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T06:03:55Z","timestamp":1794895435313,"version":"4.9.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Institutes of Health, United States"},{"name":"Emory University"},{"name":"Emory University and Children\u2019s Healthcare of Atlanta"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-26263-y","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T11:25:24Z","timestamp":1765193124000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["People with cystic fibrosis with high sputum neutrophil elastase on elexacaftor-tezacaftor-ivacaftor exhibit worse pulmonary function and pro-inflammatory airway milieu"],"prefix":"10.1038","volume":"15","author":[{"given":"Alexandre","family":"Cammarata-Mouchtouris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego Moncada","family":"Giraldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genoah L.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria M.","family":"Parrilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan O.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent D.","family":"Giacalone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten A.","family":"Cottrill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rabindra","family":"Tirouvanziam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D.","family":"Chandler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,8]]},"reference":[{"key":"26263_CR1","doi-asserted-by":"publisher","unstructured":"Ong, T. & Ramsey, B. Cystic Fibrosis: A Review. JAMA 329(21), https:\/\/doi.org\/10.1001\/jama.2023.8120 (2023).","DOI":"10.1001\/jama.2023.8120"},{"key":"26263_CR2","doi-asserted-by":"publisher","unstructured":"Grasemann, H. & Ratjen, F. Cystic fibrosis. N. Engl. J. Med. 389 (18). https:\/\/doi.org\/10.1056\/NEJMra2216474 (2023).","DOI":"10.1056\/NEJMra2216474"},{"key":"26263_CR3","doi-asserted-by":"publisher","unstructured":"Burgel, P. et al. Rapid Improvement after Starting Elexacaftor-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease. Am. J. Respir. Crit Care Med. 204(1), https:\/\/doi.org\/10.1164\/rccm.202011-4153OC (2021).","DOI":"10.1164\/rccm.202011-4153OC"},{"key":"26263_CR4","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-042921-021447","author":"S Jia","year":"2022","unstructured":"Jia, S. & Taylor-Cousar, J. Cystic fibrosis modulator therapies. Annu. Rev. Med. https:\/\/doi.org\/10.1146\/annurev-med-042921-021447 (2022).","journal-title":"Annu. Rev. Med."},{"key":"26263_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2023.102248","author":"A Tiotiu","year":"2023","unstructured":"Tiotiu, A., Ioan, I. & Billon, Y. Effects of elexacaftor-tezacaftor-ivacaftor on daily treatment burden and airflow obstruction in adults with cystic fibrosis. Pulm. Pharmacol. Ther. https:\/\/doi.org\/10.1016\/j.pupt.2023.102248 (2023).","journal-title":"Pulm. Pharmacol. Ther."},{"key":"26263_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2023.10.010","author":"S Donaldson","year":"2023","unstructured":"Donaldson, S. et al. Effect of elexacaftor\/tezacaftor\/ivacaftor on mucus and mucociliary clearance in cystic fibrosis. J. Cyst. Fibrosis: Official J. Eur. Cyst. Fibros. Soc. https:\/\/doi.org\/10.1016\/j.jcf.2023.10.010 (2023).","journal-title":"J. Cyst. Fibrosis: Official J. Eur. Cyst. Fibros. Soc."},{"key":"26263_CR7","doi-asserted-by":"publisher","unstructured":"Casey, M. et al. Effect of elexacaftor\/tezacaftor\/ivacaftor on airway and systemic inflammation in cystic fibrosis. Thorax 78\u00a0(8), https:\/\/doi.org\/10.1136\/thorax-2022-219943 (2023).","DOI":"10.1136\/thorax-2022-219943"},{"key":"26263_CR8","doi-asserted-by":"publisher","unstructured":"Schaupp, L. et al. Longitudinal effects of elexacaftor\/tezacaftor\/ivacaftor on sputum viscoelastic properties, airway infection and inflammation in patients with cystic fibrosis. Eur. Respir. J. 62\u00a0(2), https:\/\/doi.org\/10.1183\/13993003.02153-2022 (2023).","DOI":"10.1183\/13993003.02153-2022"},{"key":"26263_CR9","doi-asserted-by":"publisher","unstructured":"Lepissier, A. et al. Moving the dial on airway inflammation in response to Trikafta in adolescents with cystic fibrosis. Am. J. Respir. Crit Care Med. 207 (6). https:\/\/doi.org\/10.1164\/rccm.202210-1938LE (2023).","DOI":"10.1164\/rccm.202210-1938LE"},{"key":"26263_CR10","doi-asserted-by":"publisher","unstructured":"Vuyst, R. D., Bennard, E., Kam, C., McKinzie, C. & Esther, C. Elexacaftor\/tezacaftor\/ivacaftor treatment reduces airway inflammation in cystic fibrosis. Pediatr. Pulmonol. 58 (5). https:\/\/doi.org\/10.1002\/ppul.26334 (2023).","DOI":"10.1002\/ppul.26334"},{"key":"26263_CR11","doi-asserted-by":"publisher","unstructured":"Sheikh, S. et al. Impact of elexacaftor-tezacaftor-ivacaftor on bacterial colonization and inflammatory responses in cystic fibrosis. Pediatr. Pulmonol. 58(3), https:\/\/doi.org\/10.1002\/ppul.26261 (2023).","DOI":"10.1002\/ppul.26261"},{"key":"26263_CR12","doi-asserted-by":"publisher","unstructured":"Quinn, R. et al. Neutrophilic proteolysis in the cystic fibrosis lung correlates with a pathogenic microbiome. Microbiome 7(1), https:\/\/doi.org\/10.1186\/s40168-019-0636-3 (2019).","DOI":"10.1186\/s40168-019-0636-3"},{"key":"26263_CR13","doi-asserted-by":"publisher","unstructured":"Sosinski, L. et al. A restructuring of Microbiome niche space is associated with Elexacaftor-Tezacaftor-Ivacaftor therapy in the cystic fibrosis lung. J. Cyst. Fibrosis: Official J. Eur. Cyst. Fibros. Soc. 21 (6). https:\/\/doi.org\/10.1016\/j.jcf.2021.11.003 (2022).","DOI":"10.1016\/j.jcf.2021.11.003"},{"key":"26263_CR14","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-3356170\/v1","author":"C Martin","year":"2023","unstructured":"Martin, C. et al. Longitudinal microbial and molecular dynamics in the cystic fibrosis lung after Elexacaftor-Tezacaftor-Ivacaftor therapy. Res. Square. https:\/\/doi.org\/10.21203\/rs.3.rs-3356170\/v1 (2023).","journal-title":"Res. Square"},{"issue":"3","key":"26263_CR15","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1183\/20734735.012717","volume":"13","author":"B Cooper","year":"2017","unstructured":"Cooper, B. et al. The global lung function initiative (GLI) network: bringing the world\u2019s respiratory reference values together. Breathe (Sheff). 13 (3), e56\u2013e64. https:\/\/doi.org\/10.1183\/20734735.012717 (2017). From NLM.","journal-title":"Breathe (Sheff)"},{"key":"26263_CR16","doi-asserted-by":"publisher","unstructured":"Forrest, O. et al. Frontline science: pathological conditioning of human neutrophils recruited to the airway milieu in cystic fibrosis. J. Leukoc. Biol. 104 (4). https:\/\/doi.org\/10.1002\/JLB.5HI1117-454RR (2018).","DOI":"10.1002\/JLB.5HI1117-454RR"},{"key":"26263_CR17","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01910-2017","author":"A Dittrich","year":"2018","unstructured":"Dittrich, A. et al. Elastase activity on sputum neutrophils correlates with severity of lung disease in cystic fibrosis. Eur. Respir. J. https:\/\/doi.org\/10.1183\/13993003.01910-2017 (2018).","journal-title":"Eur. Respir. J."},{"key":"26263_CR18","doi-asserted-by":"publisher","unstructured":"Chandler, J. et al. Myeloperoxidase oxidation of methionine associates with early cystic fibrosis lung disease. Eur. Respir. J. 52 (4). https:\/\/doi.org\/10.1183\/13993003.01118-2018 (2018).","DOI":"10.1183\/13993003.01118-2018"},{"issue":"9","key":"26263_CR19","doi-asserted-by":"publisher","first-page":"6465","DOI":"10.1074\/jbc.M112.418970","volume":"288","author":"A Chapman","year":"2013","unstructured":"Chapman, A. et al. Ceruloplasmin is an endogenous inhibitor of myeloperoxidase. J. Biol. Chem. 288 (9), 6465\u20136477. https:\/\/doi.org\/10.1074\/jbc.M112.418970 (2013). From NLM.","journal-title":"J. Biol. Chem."},{"key":"26263_CR20","doi-asserted-by":"publisher","unstructured":"Giacalone, V. et al. Pilot study of inflammatory biomarkers in matched induced sputum and Bronchoalveolar lavage of 2-year-olds with cystic fibrosis. Pediatr. Pulmonol. 57 (9). https:\/\/doi.org\/10.1002\/ppul.26023 (2022).","DOI":"10.1002\/ppul.26023"},{"key":"26263_CR21","doi-asserted-by":"publisher","unstructured":"Kim, S. et al. Substrate-dependent metabolomic signatures of myeloperoxidase activity in airway epithelial cells: implications for early cystic fibrosis lung disease. Free Radic. Biol. Med. 206 https:\/\/doi.org\/10.1016\/j.freeradbiomed.2023.06.021 (2023).","DOI":"10.1016\/j.freeradbiomed.2023.06.021"},{"issue":"W1","key":"26263_CR22","doi-asserted-by":"publisher","first-page":"W388","DOI":"10.1093\/nar\/gkab382","volume":"49","author":"Z Pang","year":"2021","unstructured":"Pang, Z. et al. MetaboAnalyst 5.0: narrowing the gap between Raw spectra and functional insights. Nucleic Acids Res. 49 (W1), W388\u2013w396. https:\/\/doi.org\/10.1093\/nar\/gkab382 (2021). From NLM.","journal-title":"Nucleic Acids Res."},{"key":"26263_CR23","doi-asserted-by":"publisher","unstructured":"Chandler, J. & Esther, C. Metabolomics of airways disease in cystic fibrosis. Curr. Opin. Pharmacol. 65 https:\/\/doi.org\/10.1016\/j.coph.2022.102238 (2022).","DOI":"10.1016\/j.coph.2022.102238"},{"key":"26263_CR24","doi-asserted-by":"publisher","unstructured":"Giacalone, V., Dobosh, B., Gaggar, A., Tirouvanziam, R. & Margaroli, C. Immunomodulation in cystic fibrosis: why and how? Int. J. Mol. Sci. 21 (9). https:\/\/doi.org\/10.3390\/ijms21093331 (2020).","DOI":"10.3390\/ijms21093331"},{"key":"26263_CR25","doi-asserted-by":"publisher","unstructured":"Margaroli, C. & Tirouvanziam, R. Neutrophil plasticity enables the development of pathological microenvironments: implications for cystic fibrosis airway disease. Mol. Cell. Pediatr. 3 (1). https:\/\/doi.org\/10.1186\/s40348-016-0066-2 (2016).","DOI":"10.1186\/s40348-016-0066-2"},{"key":"26263_CR26","doi-asserted-by":"publisher","unstructured":"Tirouvanziam, R. et al. Profound functional and signaling changes in viable inflammatory neutrophils homing to cystic fibrosis airways. Proc. Natl. Acad. Sci. U.S.A. 105(11), https:\/\/doi.org\/10.1073\/pnas.0712386105 (2008).","DOI":"10.1073\/pnas.0712386105"},{"key":"26263_CR27","doi-asserted-by":"publisher","unstructured":"Laval, J., Ralhan, A. & Hartl, D. Neutrophils in cystic fibrosis. Biol. Chem. 397(6), https:\/\/doi.org\/10.1515\/hsz-2015-0271 (2016).","DOI":"10.1515\/hsz-2015-0271"},{"key":"26263_CR28","doi-asserted-by":"publisher","unstructured":"Bruce, M. et al. Biochemical and pathologic evidence for proteolytic destruction of lung connective tissue in cystic fibrosis. Am. Rev. Respir. Dis. 132(3), https:\/\/doi.org\/10.1164\/arrd.1985.132.3.529 (1985).","DOI":"10.1164\/arrd.1985.132.3.529"},{"issue":"1\u20132","key":"26263_CR29","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.cell.2018.12.002","volume":"176","author":"K Genschmer","year":"2019","unstructured":"Genschmer, K. et al. Activated PMN exosomes: pathogenic entities causing matrix destruction and disease in the lung. Cell 176 (1\u20132), 113\u2013126e115. https:\/\/doi.org\/10.1016\/j.cell.2018.12.002 (2019). From NLM.","journal-title":"Cell"},{"key":"26263_CR30","doi-asserted-by":"publisher","unstructured":"Dalen, C. V., Whitehouse, M., Winterbourn, C. & Kettle, A. Thiocyanate and chloride as competing substrates for myeloperoxidase. Biochem. J. 327 (Pt(2), https:\/\/doi.org\/10.1042\/bj3270487 (1997).","DOI":"10.1042\/bj3270487"},{"key":"26263_CR31","doi-asserted-by":"publisher","unstructured":"Mayer-Hamblett, N. et al. Association between pulmonary function and sputum biomarkers in cystic fibrosis. Am. J. Respir. Crit Care Med. 175 (8). https:\/\/doi.org\/10.1164\/rccm.200609-1354OC (2007).","DOI":"10.1164\/rccm.200609-1354OC"},{"key":"26263_CR32","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.freeradbiomed.2017.09.028","volume":"113","author":"N Dickerhof","year":"2017","unstructured":"Dickerhof, N. et al. Oxidative stress in early cystic fibrosis lung disease is exacerbated by airway glutathione deficiency. Free Radic Biol. Med. 113, 236\u2013243. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2017.09.028 (2017). From NLM.","journal-title":"Free Radic Biol. Med."},{"issue":"2","key":"26263_CR33","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.jcf.2016.10.012","volume":"16","author":"N Dickerhof","year":"2017","unstructured":"Dickerhof, N. et al. Oxidized glutathione and uric acid as biomarkers of early cystic fibrosis lung disease. J. Cyst. Fibros. 16 (2), 214\u2013221. https:\/\/doi.org\/10.1016\/j.jcf.2016.10.012 (2017). From NLM.","journal-title":"J. Cyst. Fibros."},{"key":"26263_CR34","doi-asserted-by":"publisher","unstructured":"Lepissier, A. et al. Inflammation biomarkers in sputum for clinical trials in cystic fibrosis: current Understanding and gaps in knowledge. J. Cyst. Fibrosis: Official J. Eur. Cyst. Fibros. Soc. 21 (4). https:\/\/doi.org\/10.1016\/j.jcf.2021.10.009 (2022).","DOI":"10.1016\/j.jcf.2021.10.009"},{"key":"26263_CR35","doi-asserted-by":"publisher","unstructured":"Gars, M. L. et al. Neutrophil elastase degrades cystic fibrosis transmembrane conductance regulator via calpains and disables channel function in vitro and in vivo. Am. J. Respir. Crit Care Med. 187 (2). https:\/\/doi.org\/10.1164\/rccm.201205-0875OC (2013).","DOI":"10.1164\/rccm.201205-0875OC"},{"key":"26263_CR36","doi-asserted-by":"publisher","unstructured":"Harris, J. et al. Changes in airway Microbiome and inflammation with Ivacaftor treatment in patients with cystic fibrosis and the G551D mutation. Annals Am. Thorac. Soc. 17 (2). https:\/\/doi.org\/10.1513\/AnnalsATS.201907-493OC (2020).","DOI":"10.1513\/AnnalsATS.201907-493OC"},{"key":"26263_CR37","doi-asserted-by":"publisher","unstructured":"Hisert, K. et al. Restoring cystic fibrosis transmembrane conductance regulator function reduces airway bacteria and inflammation in people with cystic fibrosis and chronic lung infections. Am. J. Respir. Crit Care Med. 195 (12). https:\/\/doi.org\/10.1164\/rccm.201609-1954OC (2017).","DOI":"10.1164\/rccm.201609-1954OC"},{"key":"26263_CR38","doi-asserted-by":"publisher","unstructured":"Westh\u00f6lter, D. et al. Plasma levels of chemokines decrease during elexacaftor\/tezacaftor\/ivacaftor therapy in adults with cystic fibrosis. Heliyon 10 (1). https:\/\/doi.org\/10.1016\/j.heliyon.2023.e23428 (2023).","DOI":"10.1016\/j.heliyon.2023.e23428"},{"key":"26263_CR39","doi-asserted-by":"publisher","unstructured":"Ford, B. et al. Functional and transcriptional adaptations of blood monocytes recruited to the cystic fibrosis airway microenvironment in vitro. Int. J. Mol. Sci. 22 (5). https:\/\/doi.org\/10.3390\/ijms22052530 (2021).","DOI":"10.3390\/ijms22052530"},{"issue":"2","key":"26263_CR40","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1378\/chest.14-1800","volume":"148","author":"CJ Esther","year":"2015","unstructured":"Esther, C. J. et al. Metabolomic evaluation of neutrophilic airway inflammation in cystic fibrosis. Chest 148 (2), 507\u2013515. https:\/\/doi.org\/10.1378\/chest.14-1800 (2015). From NLM.","journal-title":"Chest"},{"key":"26263_CR41","doi-asserted-by":"publisher","unstructured":"Ingersoll, S. et al. Mature cystic fibrosis airway neutrophils suppress T cell function: evidence for a role of arginase 1 but not programmed death-ligand 1. J. Immunol. (Baltimore Md.\u202f: 1950) 194(11), https:\/\/doi.org\/10.4049\/jimmunol.1500312 (2015).","DOI":"10.4049\/jimmunol.1500312"},{"key":"26263_CR42","unstructured":"Foundation, C. F. Patient registry; (2022)."},{"key":"26263_CR43","doi-asserted-by":"publisher","unstructured":"Sch\u00fctz, K. et al. Spirometric and anthropometric improvements in response to elexacaftor\/tezacaftor\/ivacaftor depending on age and lung disease severity. Front. Pharmacol. 14 https:\/\/doi.org\/10.3389\/fphar.2023.1171544 (2023).","DOI":"10.3389\/fphar.2023.1171544"},{"key":"26263_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2023.11.008","author":"E Gill","year":"2023","unstructured":"Gill, E. et al. A longitudinal analysis of respiratory symptoms in people with cystic fibrosis with advanced lung disease on and off ETI. J. Cyst. Fibrosis: Official J. Eur. Cyst. Fibros. Soc. https:\/\/doi.org\/10.1016\/j.jcf.2023.11.008 (2023).","journal-title":"J. Cyst. Fibrosis: Official J. Eur. Cyst. Fibros. Soc."},{"key":"26263_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2023.05.009","author":"A Wang","year":"2023","unstructured":"Wang, A. et al. Sex differences in outcomes of people with cystic fibrosis treated with elexacaftor\/tezacaftor\/ivacaftor. J. Cyst. Fibrosis: Official J. Eur. Cyst. Fibros. Soc. https:\/\/doi.org\/10.1016\/j.jcf.2023.05.009 (2023).","journal-title":"J. Cyst. Fibrosis: Official J. Eur. Cyst. Fibros. Soc."},{"key":"26263_CR46","doi-asserted-by":"publisher","unstructured":"Kerem, E. et al. Factors associated with FEV1 decline in cystic fibrosis: analysis of the ECFS patient registry. Eur. Respir. J. 43 (1). https:\/\/doi.org\/10.1183\/09031936.00166412 (2014).","DOI":"10.1183\/09031936.00166412"},{"key":"26263_CR47","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/978-3-030-68748-9_14","volume":"1304","author":"P Silveyra","year":"2021","unstructured":"Silveyra, P., Fuentes, N. & Bauza, D. R. Sex and gender differences in lung disease. Adv. Exp. Med. Biol. 1304, 227\u2013258. https:\/\/doi.org\/10.1007\/978-3-030-68748-9_14 (2021). From NLM.","journal-title":"Adv. Exp. Med. Biol."},{"key":"26263_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(23)00324-7","author":"K Hisert","year":"2023","unstructured":"Hisert, K. et al. Understanding and addressing the needs of people with cystic fibrosis in the era of CFTR modulator therapy. Lancet Respiratory Med. https:\/\/doi.org\/10.1016\/S2213-2600(23)00324-7 (2023).","journal-title":"Lancet Respiratory Med."},{"key":"26263_CR49","doi-asserted-by":"publisher","unstructured":"Desai, M. et al. Who are the 10%? - Non eligibility of cystic fibrosis (CF) patients for highly effective modulator therapies. Respir. Med. 199, https:\/\/doi.org\/10.1016\/j.rmed.2022.106878 (2022).","DOI":"10.1016\/j.rmed.2022.106878"},{"key":"26263_CR50","doi-asserted-by":"publisher","unstructured":"Ensinck, M. & Carlon, M. One Size Does Not Fit All: The Past, Present and Future of Cystic Fibrosis Causal Therapies. Cells 11(12), https:\/\/doi.org\/10.3390\/cells11121868 (2022).","DOI":"10.3390\/cells11121868"},{"key":"26263_CR51","doi-asserted-by":"publisher","unstructured":"Margaroli, C. et al. Transcriptional firing represses bactericidal activity in cystic fibrosis airway neutrophils. Cell. Rep. Med. 2(4), https:\/\/doi.org\/10.1016\/j.xcrm.2021.100239 (2021).","DOI":"10.1016\/j.xcrm.2021.100239"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-26263-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-26263-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-26263-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T14:58:13Z","timestamp":1767884293000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-26263-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,8]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["26263"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-26263-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,8]]},"assertion":[{"value":"20 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"43430"}}